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In this study, a novel approach for compression of matrix pellets into disintegrating tablets has been studied 
in an attempt to overcome the issues pertaining to rupture of polymer coat during compression of reservoir-
type pellets. Extended release matrix pellets were prepared by the extrusion/spheronization technique using 
commercially available aqueous dispersions of ethyl cellulose, acrylic polymers and sodium alginate at 10%, 
20% and 30%w/w levels. Sertraline hydrochloride was used as the model drug and an in vitro release profile of 
12 h was targeted. Tablets containing matrix pellets were prepared by the direct compression process. Acceptance 
Value, a pharmacopeial test, was applied to study the uniformity of drug distribution. Effect of compression 
force (2-6 kN), extrusion screen aperture size, diluent blend composition and pellet percentage on drug release 
and acceptance value were studied. As polymer is uniformly distributed within each pellet, the drug release 
pattern from uncompressed pellets was comparable to compressed tablets. Surface morphological changes due 
to calcium chloride treatment were observed using Scanning electron microscopy. The pellet segregated from 
the surface of the tablet was found to be flattened in the direction of applied compression force with minor 
deformities. In conclusion, matrix pellets can constitute an alternative approach to reservoir-type pellets in 
obtaining disintegrating tablets for extended delivery of drugs.
Uniterms: Pellets/extended release/evaluation. Pellets/obtention. Pellets/compression. Extrusion/spheronization 
technique.
Nesse trabalho, estudou-se nova abordagem para a compressão de matrizes de péletes em comprimidos 
desintegrantes, com o intuito de resolver os problemas relativos à ruptura do polímero de revestimento durante 
a compressão dos péletes do tipo reservatório. Matrizes de péletes de liberação estendida foram preparadas pela 
técnica de extrusão/esferonização, utilizando dispersões aquosas comercialmente disponíveis de etil celulose, 
polímeros acrílicos e alginato de sódio a 10%, 20% e 30% p/p. O cloridrato de sertralina foi utilizado como 
fármaco modelo e focalizou-se no perfil de liberação in vitro de 12 horas. Os comprimidos contendo matrizes 
de péletes foram preparados pelo processo de compressão direta. O valor de aceitação, teste farmacopéico, foi 
aplicado para estudar a uniformidade de distribuição do fármaco. O efeito da força de compressão (2-6 kN), o 
tamanho da abertura de extrusão, a composição da mistura diluente, a porcentagem de pélete na liberação de 
fármaco e o valor de aceitação foram estudados. Como o polímero é uniformemente distribuído dentro de cada 
pélete, o padrão de liberação do fármaco dos péletes não-comprimidos foi comparável àquele dos comprimidos.  
As mudanças morfológicas da superfície devidas ao tratamento com cloreto de cálcio foram observadas utilizando-
se a microscopia eletrônica de varredura. O pélete segregado da superfície do comprimido mostrou-se plano em 
direção à força de compressão aplicada com menores deformidades. Em conclusão, os péletes matriz podem se 
constituir em abordagem alternativa para péletes do tipo reservatório na obtenção de comprimidos desintegrantes 
para fármacos de liberação estendida.
Unitermos: Pellets/liberação prolongada/avaliação. Pellets/obtenção. Pellets/compressão. Técnica de extrusão/
esferonização.
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INTRODUCTION
Multiple unit extended release dosage forms are 
preferred over single unit dosage forms as they spread 
uniformly throughout the gastrointestinal tract produc-
ing less variability and lower risk of local irritation due 
to the minute amount of drug carried (Bodmeier, 1997; 
Bechgaard, Nielsen, 1978). A multi-unit particulate sys-
tem (MUPS) comprises a tablet dosage form wherein 
pellets are compressed into tablets along with appropriate 
excipients or cushioning agents. Conventional design of 
oral modified release systems involves coating of spheri-
cal pellets with polymer that regulates the rate and extent 
of drug release. However, there are some disadvantages 
with capsules, such as feasibility of tampering, difficul-
ties in esophageal transport, and higher production costs 
(capsule shells), hence, such pellets are compressed into 
disintegrating tablets. Tablets can be prepared at a lower 
cost because of the higher production rate of tablet presses 
(Murthy, Vijaya, Ratna, 2008). In addition, tablets con-
taining multiparticulates can be scored without losing 
their controlled release properties, which allows a more 
flexible dosing regimen (Bodmeier, 1997). The formula-
tion challenge producing tablets from pellets is obtaining 
uniformity of drug content in the tablet and maintaining 
the desired drug release after compression. The application 
of compression pressure can lead to structural changes in 
the film coating consequently altering drug release. Most 
of the studies on the compression of pellets coated with 
ethyl cellulose and acrylic polymers have revealed damage 
to the coating with loss of the extended release properties 
(Bansal, Vasireddy, Parikh, 1993). Compression of pellets 
at higher force is reported to reduce the release from the 
tablets due to fusion of pellets (Lopez-Rodriguez et al., 
1993) whereas the release of drug was found to be faster 
from tablets due to the brittle nature of pellets (Branka et 
al., 2009). Smaller pellets were reported to be less affected 
by the compression process than larger pellets. Use of 
microcrystalline cellulose and polyethylene glycol 3350 
produced rapidly disintegrating tablets containing pellets, 
with lowest change in the drug release pattern after tablet-
ing (Torrado, Paronen, 1994). Various techniques have 
previously been explored in a bid to reduce the damage 
to rate-controlling polymer film. However, a recent study 
involved the use of polyethylene glycol as a cushioning 
agent and tablet compression at elevated temperature as 
an alternative to using reservoir-type pellets (Wieslaw, 
Jaroslaw, Ilona, 2010).
Extrusion/spheronization is an established tech-
nique for producing spherical pellets in a typical size 
range of between 0.5 and 2 mm. Various polymers have 
been employed for preparing pellets using the extrusion 
spheronization technique (Pornsak et al., 2007; Helton et 
al., 2005). In the present study, Sertraline Hydrochloride 
(SRT), commonly prescribed for depressive illness, was 
used as the model drug. There are various reports in the 
literature on the side effects associated with sertraline 
treatment at prescribed doses, such as severe nausea, 
headache, diarrhea, sexual dysfunction, tremor, dizzi-
ness and fatigue (Grimsley, Jann, 1992; Dogan, 1991). A 
granted patent publication US 6,899,896B1 (Curatolo et 
al., 2005) claimed to produce better patient compliance 
when sertraline was released at a specified rate from a 
hydrogel-based dosage form. The in vitro release profile 
of up to 12 h was found to increase patient compliance and 
the therapeutic efficacy of sertraline. Hence in the present 
study, commonly used extended release polymers such as 
sodium alginate, aqueous dispersion of ethyl cellulose and 
acrylic polymers were evaluated to prepare matrix pellets 
(Hodsdon et al., 1995; Bhagat et al., 1990).
The objective of this study was to investigate the 
possibility of producing extended release matrix pellets by 
the extrusion/spheronization technique using Aquacoat® 
ECD 30, Eudragit® L 30D 55 and Eudragit® NM 30D, So-
dium alginate (Keltone® LV CR) as polymers to achieve in 
vitro drug release of up to 12 h. These matrix pellets were 
compressed into tablets which should disintegrate rapidly 
in the dissolution medium. The study also investigated the 
effect of formulation variables on the uniformity of the 
tablet content and in vitro drug release profile.
MATERIALS AND METHODS
Materials
Sertraline hydrochloride was obtained from Matrix 
Laboratories Ltd, India. Sodium alginate (Keltone® LVCR) 
was procured from ISP Corporation India. Eudragit® L 
30D 55 and Eudragit® NM 30 D grades were obtained 
from Evonik India Ltd, Mumbai. Aquacoat® ECD, (30 
%w/w dispersion) was obtained from FMC Biopolymer. 
Other excipients used in the pellet preparation and tablet 
compression were obtained from Matrix Laboratories Ltd, 
Hyderabad, India.
Methods
Preparation of Matrix pellets by extrusion/
spheronization
Matrix pellets were prepared using the various com-
positions shown in Table I. All the batches were of 2000 
units and 100 mg in strength. First, dry powder mixture 
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was prepared by mixing sertraline, microcrystalline cel-
lulose and hydroxypropyl cellulose (wherever required) in 
a laboratory scale Rapid mixer granulator [Allen Bradley 
5L, USA] at slow impeller speed for around 10 min. To 
granulate this blend, an aqueous dispersion of ethyl cel-
lulose and eudragit polymers were used. Additional water, 
if required, was added during granulation to obtain a wet 
mass suitable for extrusion. While using the sodium algi-
nate polymer, water was used as the binding liquid. The 
wet mass was extruded through a screen extruder [Multi-
gran MG 55, Fugi Paudal Co Ltd Japan] equipped with a 
standard screen having an 0.8 mm diameter aperture, and 
rollers rotating at 30 rpm. The extrudates were transferred 
to the spheronizer [QJ 230T-1, Fugi Paudal Co Ltd Japan.] 
equipped with a crosshatch plate [1mm] and processed at 
850 rpm rotation speed for the desired time (415 min). The 
spheronization time was varied according to the polymer 
used in the pellet preparations where the longest spheroni-
zation time was required for the composition containing 
30% w/w sodium alginate. The resultant pellets were 
dried in a fluid bed dryer [Rapid dryer, Retsch, Germany] 
with an inlet air flow at 50 0C for about 20-30 min. The 
dried pellets were sifted and retained on an ASTM # 20 
mesh (841 µ) and the fines below # 40 mesh (420 µ) were 
discarded. The process yield was calculated from the 
quantity of fraction of dried pellets obtained after sifting 
(Pai, Kohli, 2011).
Calcium ion complexation
Wet pellets (about 320 g) obtained from (#F 11) 
composition were poured into 500 mL of calcium chloride 
solution of different concentrations (10% w/w, 20% w/w 
and saturated solution of calcium chloride). The pellets 
were allowed to form gelatinous precipitate by chemical 
reaction between sodium alginate and calcium chloride on 
the surface of the pellets. The pellets were left under slow 
stirring for 10 min and then filtered, washed with distilled 
water and vacuum dried.
Preparation of MUPS tablets
MUPS tablets were prepared by the direct compres-
sion approach using the compositions shown in Table II. 
For this, 320g of calcium chloride-treated pellets were 
mixed with microcrystalline cellulose, polyethylene gly-
col and crospovidone in a laboratory scale blender [Conta 
Blender, Bowman & Archer] for 10 min. Finally, magne-
sium stearate passed through a 250 µm sieve was added to 
the mixture and blended for 5 min. The degree of filling of 
the blending vessel was 50% by volume to ensure proper 
mixing. The tablets of 1066± 50 mg were compressed 
using one set of 19.5 X 9.5 mm capsule shaped, biconvex 
tooling on a 12-station automated single rotary compres-
sion machine [Smart Press, SRC 10i, Pacific Industries, 
India]. The compression machine is equipped to measure 
the compression forces applied to the blend. Considering 
the criticality of the compression process, the machine 
speed was set to 10 rpm. Minimum gap was maintained 
between the turret and the feed frame to minimize the 
physical stress on the blend during rotation. Tablets were 
compressed at different compression forces in a 2-6 kN 
range in order to obtain tablets with a crushing strength 
ranging from 80 to 240 N.
Characterization of pellets and compressed tablets
· Density and friability
The bulk density was determined by pouring pellets 
into a previously weighed 10 ml graduated glass cylinder 
TABLE I - Composition of extended release matrix pellets using various polymers
Composition (mg) #F1 #F2 #F3 #F4 #F5 #F6 #F7 #F8 #F9 #F10 #F11 #F12
Sertralinea 112 112 112 112 112 112 112 112 112 112 112 112
Microcrystalline 
Cellulose Avicel PH102)
166 134 102 166 134 102 166 134 102 176 144 112
Hydroxypropyl cellulose 10 10 10 10 10 10 10 10 10 x x x
Aquacoat ECD 30 32 64 96 x x X x x X x x x
Eudragit L 30D 55 x x x 32 64 96 x x x x x x
Eudragit NM 30D x x x x x X 32 64 96 x x x
Sodium Alginate x x x x x X x x x 32 64 96
Water qs qs qs qs qs qs qs qs qs qs qs qs
Total Weight (mg) 320 320 320 320 320 320 320 320 320 320 320 320
a Weight of hydrochloride salt equivalent to 100 mg sertraline base. qs-Quantity sufficient
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where the weight of the pellets needed to occupy a 10ml 
volume was noted. The bulk density was calculated by the 
ratio of weight to occupied volume.
Friability was measured using Electrolab Friabil-
ity testing apparatus [Electrolab Ltd, Mumbai, India] by 
tumbling 10g of the pellets for 4 min at 25rpm. The tested 
pellets were gently tapped on an ASTM # 40mesh to re-
move the fines generated and weight loss was measured. 
For testing the friability of the tablets, ten tablets were 
initially weighed on an analytical balance, transferred to 
the friabilator and run for 4 min. The tablets were weighed 
after removing the powdered dust, and weight lost during 
testing was calculated.
· Sphericity
The sphericity of the pellets was measured using the 
simplest approach described by Lovgren and Lundberg 
(Lovgren, Lundberg, 1989), by measuring the length and 
width of the two dimensional image of the pellets on an 
optical microscope [Olympus BX55TF, Japan]. The shape 
factor was expressed as % Sphericity, where 100 % cor-
responds to a perfect circle. The longest length and breadth 
of the pellets were measured accurately when the pellets 
were rested in their most stable position. A frequency dis-
tribution of the percent ratio of length to breadth of 100 
pellets was calculated and the Sphericity (S) was expressed 
(Eriksson, Nystrom, Aldeborn, 1993).
· Hardness testing
The force required to fracture a tablet was measured 
using a tablet hardness tester [Dr Schleuniger, Pharmatron 
8M]. Hardness of at least 10 tablets from each formulation 
was measured and reported as a range.
· Disintegration testing
The disintegration time of the tablet was tested us-
ing USP disintegration apparatus on 6 tablets from each 
composition. [Electrolab Disintegration Apparatus, India]. 
Distilled water was used as the medium at a temperature 
of 37 0C. The time taken until no material from any of the 
tablets was left on the mesh was recorded.
· In vitro dissolution testing
In vitro release study of the pellets and compressed 
tablets was performed using acetate buffer pH 4.5 in a 
dissolution test apparatus [Electrolab, Mumbai, India]. 
The test employed 900 mL of the specified buffer at 37 °C 
and a USP Type II apparatus (paddle) rotating at 50 rpm. 
Samples were collected at 1, 2, 4, 6, 8, 10 and 12 h inter-
vals and analyzed by a UV-Visible spectrophotometer 
[UV 2450, Shimadzu Corporation, Japan] at 273nm. Dis-
solution of pellets and MUPS tablets was conducted for 6 
representative samples.
· Drug content analysis
To determine drug content, an amount of crushed 
pellets equivalent to 100 mg of sertraline was weighed into 
a flask (1000 mL) and extracted with a minimum quantity 
of methanol and made up to volume with acetate buffer 
pH 4.5 then sonicated for around 30 min. UV absorbance 
of the solution filtered through 0.43µ filters was measured 
using a UV-Visible spectrophotometer [UV 2450, Shi-
madzu Corporation, Japan] at 273nm (λmax). To avoid 
the influence of excipients, the placebo blend was also 
treated similarly and kept as a blank. Standard solution 
was prepared by accurately weighing [Mettler Toledo, 
India] 100 mg of sertraline and following a similar dilution 
procedure. From the absorbance of the test solution, the 
amount of drug in the solution was calculated.
· Acceptance Value
Acceptance Value is a test recommended by the 
USP 30 [2007] for evaluating content uniformity in dos-
age forms. As MUPS tableting involves the compression 
of two varying density components together, achieving 
content uniformity within the pharmacopoeial limits is 
a challenging task (Flament et al., 1994). Hence, the Ac-
ceptance Value was considered as a tool for evaluating 
TABLE II - Composition of MUPS tablets prepared using calcium chloride-treated pellets
Composition (mg) TAB #1 TAB #2 TAB #3 TAB #4 TAB #5
Sertraline Pellets b 320 320 320 320 320
Microcrystalline Cellulose Avicel 102 646 446 446 263 78
Microcrystalline Cellulose Avicel PH101 - 200 - 117 35
Milled Avicel PH 102 - 200 - -
Polyethylene glycol, 6000 64 64 64 64 64
Crospovidone 31 31 31 31 31
Magnesium Stearate 5 5 5 5 5 
Total weight (mg) 1066 1066 1066 800 533
Percent of pellets (%w/w) 30 30 30 40 60
Acceptance Value 18.7 12.2 14 NP NP
bComposition #F11, NP; Not performed
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uniformity and content of 10 individual tablets, measured 
with the method described above. Acceptance value was 
calculated as per the equation below.
 AV= |M-X| + kS (1)
Where k is acceptability constant (k = 2.4 while test-
ing 10 tablets), S is standard deviation of assay values of 
10 units, X is mean of the assay value. M =X when X value 
is between 98.5 -101.5%. M = 98.5 if X value is below 
98.5 and M =101.5 if X value is above 101.5. Absolute 
value for M-X is to be considered for calculation of Ac-
ceptance value.
· Scanning electron microscopy
Scanning electron microscope [Jeol, JSM 6380LV, 
Japan] was used to observe the physical properties and 
surface modification due to calcium ion complexation in 
sodium alginate-containing pellets. The untreated pellets 
were compared with the calcium chloride-treated pellets. 
Scanning electron microscopy was also used to observe the 
pellet distribution in the tablet and to evaluate the possible 
physical deformities due to the compression force applied. 
The pellets from the surface of compressed tablets which 
comes into direct contact with the tooling surface were 
separated carefully and observed under scanning electron 
microscope to observe any mechanical damage incurred 
during compression of the pellets.
Stability evaluation of compressed tablets
Accelerated stability studies were carried out on the 
MUPS tablets prepared using calcium chloride-treated pel-
lets as per ICH recommendation. The tablets were packed 
in HDPE bottles and charged in a stability chamber for a 
3M period at 40 ºC/75% RH. After completing the stabil-
ity period, the tablets were evaluated for their physical 
and chemical attributes including drug content and drug 
release profile.
RESULTS AND DISCUSSION
Preparation of matrix pellets and effect of 
polymers
The concept of compression of matrix pellets into 
disintegrating tablet dosage form was derived as a response 
to issues pertaining to compression of reservoir-type pel-
lets coated with polymers for extended release of drug. 
In reservoir-type pellets, the nature, type and amount of 
polymer coating has a significant impact on compression-
induced changes in the coating structure. Most of the stud-
ies on compression of pellets coated with polymers have 
shown damage to the coating with loss of the extended 
release properties due to rupture of the coat (Dashevsky, 
Kotler, Bodmeier, 2004) resulting in faster drug release 
(Sarisuta, Punpreuk, 1994). Polymers typically used in 
the coating of pellets are either cellulosic polymers or 
acrylic polymers. Hence, in the present study three com-
mercially available aqueous dispersions of ethyl cellulose 
(Aquacoat® ECD 30) and acrylic polymers (Eudragit® L 
30D; Eudragit® NM 30D) were evaluated in an attempt 
to develop matrix pellets with an extended drug release 
profile. For this purpose an SRT, hydroxypropyl cellulose 
and microcrystalline cellulose blend was granulated with 
aqueous dispersions of polymers [Table 1] in a rapid mixer 
granulator. Considering the aqueous granulation process, 
a higher level of microcrystalline cellulose was used in 
the composition to facilitate the extrusion spheronization 
process due to its unique water absorbing and retaining 
characteristics (Baert, Remnon, 1993).
During initial trials of granulation, operational 
variables such as kneading time and spheronization time 
were found to have a significant impact on the length of 
the extrudates and shape /size of the pellets, respectively. 
The nature of the granules suitable for extrusion was de-
cided based on the preliminary experiments. The process 
parameters were varied accordingly to obtain pellets with 
the desired properties. In order to involve minimum pro-
cess variables while using the different polymers blending 
time, binder addition time, screw feeder rate and drying 
temperature were kept constant. Based on the property of 
the polymer and its quantity in the composition, the sphe-
ronization time was varied accordingly to obtain pellets 
with suitable properties observed visually. The properties 
of the pellets prepared using 10%, 20% and 30% w/w 
polymer are given in Table III.
While preparing pellets using a lower level of poly-
mer, an additional quantity of water was added in order to 
attain the desired granule mass for extrusion. Extrusion of 
the blend containing a higher level of polymer (30% w/w) 
through the 0.8 mm screen aperture proved difficult lead-
ing to an increase in spheronization time (12-15 min). 
Polymer levels beyond 30%w/w were not evaluated as 
these were generating lengthy extrudates and leaving 
tackiness during extrusion. The drug release pattern from 
the pellets containing ethyl cellulose and acrylic polymer 
was not satisfactory (Figure 1A to 1C).
More than 85 % drug release was observed within 
4h from the pellets containing Aquacoat ECD and Eu-
dragit NM 30D. However, use of Eudragit L 30D 55 at a 
30% w/w level was able to extend the drug release to 6 h. 
This drug release phenomenon can be ascribed to the ero-
sion of polymer from the surface of the pellets and release 
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of drug from the new surface becoming dissolved in dis-
solution media. Moreover, these polymers are not soluble 
in the dissolution media employed (pH 4.5 acetate buffer) 
for in vitro drug release testing. As the desired profile was 
not obtained in the pellet stage, compression of these pel-
lets into MUPS tablet was not considered further.
Pellet preparation was done using sodium alginate, 
a widely used polymer for matrix tablets and film coat-
ings, wherein sphsronization took slightly longer time 
(8-10 min). A small quantity of water (1-3 mL) was 
sprinkled from the top of the spheronizer to avoid rapid 
drying of the pellets in the spheronization chamber. The 
dried pellets were subjected to in vitro dissolution testing 
at the specified testing conditions. Complete drug release 
was observed within 4 h (Figure 1D). The rapid dissolu-
tion from the pellets could be ascribed to the formation of 
soluble hydrogel where drug release could occur due to 
both diffusion and erosion mechanisms (Pai, Kohli, 2011).
Effect of calcium chloride
Development of pellet dosage forms containing 
sodium alginate in the presence of calcium ions has been 
reported previously (Sriamornsak, Kennedy, 2006). De-
layed extended release profiles of drug release have been 
achieved using sodium alginate in the form of beads by 
complexing it with calcium chloride (Patel, Nagle, Mur-
thy, 2008). In this approach, #F11 composition blend was 
granulated with water and wet spheroids were poured into 
a beaker containing calcium chloride solution. In vitro 
drug release from calcium chloride-treated pellets ex-
tended the release of sertraline to around 12h. Although 
there was no considerable difference in the in vitro drug 
release profile for the pellets treated with different con-
centrations of calcium chloride solution, slowest release 
was observed from the pellets treated with saturated 
calcium chloride solution (Figure 2). Cross-linking of 
the calcium ions generates an insoluble calcium alginate 
layer on the surface of the beads, reducing the entry of 
the dissolution media into the pellets. When treating 
with saturated calcium chloride solution, more calcium 
ions per unit area are available to react with the alginic 
acid moiety to form a rigid, insoluble gelatinous mass 
compared to the other two concentrations studied. As 
complexation is an instant surface phenomenon, the drug 
release from the saturated calcium chloride solution-
treated pellet was much closer to the desired drug release 
profile as illustrated in Figure 2.
TABLE III - Physical characterization data of matrix pellets prepared using extrusion/spheronization process











Aquacoat ECD F1 10 Spherical + 
fines
78.6 93.3 0.380 1.125 76 ± 8%
F2 20 Spherical 86.4 92.1 0.240 1.095 84 ± 5%
F3 30 Spherical 82.0 90.6 0.236 1.115 80± 5%
Eudragit L 30D 55 F4 10 Spherical + 
fines
72.2 89.4 0.380 1.186 76 ± 7%
F5 20 Spherical+ 
fines
84.5 90.6 0.240 1.182 81 ± 5%
F6 30 Spherical 86.8 93.4 0.288 1.195 65 ± 8%
Eudragit NM 30D F7 10 Almost 
Spherical
80.2 90.0 0.400 1.213 78 ± 9%
F8 20 Spherical 82.1 92.3 0.380 1.236 82 ± 6%
F9 30 Dumbbell-
Shaped
72.8 91.1 0.385 1.328 65 ± 7%
Sodium Alginate F10 10 Spherical 78.4 93.2 0.245 0.876 78 ± 4%
F11 20 Spherical 88.9 92.8 0.210 0.888 86 ± 5%
F12 30 Dumbbell-
Shaped
76.3 91.2 0.220 0.877 72 ± 6%
Calcium Chloride-
Treated
F10 20 Spherical - 91.9 0.180 0.886 88 ± 5%
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FIGURE 1 - In vitro dissolution profiles of sertraline from pellets containing 10 %w/w, 20 %w/w and 30 %w/w 1A: Aquacoat® 
ECD, 1B: Eudragit® NM30D, 1C: Eudragit® L30D 55, 1D: Keltone® LV CR.
Pellet characterization
Pellets obtained with all polymers tested showed 
comparable density, sphericity and friability as compiled 
in Table III. However, the density of the pellets prepared 
FIGURE 2 - In vitro dissolution profiles of sertraline from 
calcium alginate pellets treated with (-■-) 10%w/w Calcium 
chloride solution, (-♦-) 20 %w/w Calcium chloride solution and 
(-▲-) Saturated calcium chloride solution.
with sodium alginate was lower compared to pellets 
obtained from the other polymers. This observation can 
be attributed to the swelling nature of the alginate in the 
presence of water during granulation and subsequent in-
crease in porosity upon drying. The process yield of the 
desired fraction pellet was found to vary with the nature 
and level of the polymer used. The lowest process yield 
of 72.2% was observed while using 10%w/w Eudragit L 
30D 55 due to generation of the fines fraction below the 
ASTM 40 mesh. However, when using 30%w/w Eudragit 
NM 30D, the process yield was only 72.8% with rejection 
being due to retention of pellets on the upper mesh size 
(ASTM 20 mesh) given the formation of large (dumb 
bell shaped) pellets. The process yield from the rest of 
the polymer levels was comparable. Drug content of the 
pellets was found to vary from 89 to 93 %w/w consider-
ing the process loss at various stages during manufacture. 
The general observation is that the process yield was low 
due to fines generation when a low level of polymer was 
used whereas at higher levels of polymer, the process 
yield was also found to be low as a result of the larger or 
irregular-shaped pellets generated because of difficulties 
in spheronization. The shape of the pellets obtained varied 
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from spherical to elongated spherical or dumbbell shape in 
some cases. The lowest sphericity of 65% was observed in 
the pellets prepared using higher levels of polymer and the 
most spherical pellets obtained showed a sphericity value 
of 88%. The scanning electron micrographs of sodium 
alginate-containing pellets and calcium chloride-treated 
matrix pellets are shown in Figure 3.
The surface of the matrix pellets treated with cal-
cium chloride was smoother and uniformly covered with 
gelatinous mass of calcium alginate. The pellets were 
almost spherical and no significant morphological differ-
ences were observed.
Compression of core pellets into MUPS tablets
Based on the release profile of the pellets, only 
calcium chloride-treated pellets were considered for com-
pression into MUPS tablets. For compressing these pellets, 
microcrystalline cellulose was used as a filler in diluent 
blend (TAB #1) because of its cushioning property leading 
to minimum damage to the pellets during compression. Due 
to differences in the size and density of both pellets and ex-
cipients, weight variation and content uniformity problems 
are regularly observed during compression of pellets where 
these could be controlled by carefully selecting pellets with 
narrow size distribution together with excipients of similar 
size and shape. The composition of the extra granular blend 
was prepared using different grades of microcrystalline 
cellulose and evaluated for content uniformity. In one of 
the approaches, part of the microcrystalline cellulose was 
milled and replaced the original composition (Table II). 
Based on this, to obtain uniformity in drug content within 
the compressed tablets by maintaining a minimum size 
difference, pellet fractions passed through ASTM # 20 
mesh and retained over #40 mesh were used. The direct 
compression approach was used to obtain disintegrating 
tablets where the pellets were mixed with microcrystalline 
cellulose, crospovidone (PPXL) to achieve fast disinte-
gration with polyethylene glycol used as the cushioning 
agent at the ratio (Table I) shown in Table II. Percentage 
of pellets in the composition was maintained at a 30% w/w 
level based on previous studies involving compression of 
blends containing pellets from 30%w/w to 40%w/w of the 
composition (Lundqvist, Podczeck, Newton, 1998) that 
yielded satisfactory results. Tablets were compressed on a 
single rotary compression machine using one set of tool-
ing and carefully adjusting the gap between the turret and 
the feed frame to avoid pellet entrapment and subsequent 
physical damage. The tablets with the optimized compo-
sition were compressed at different compression forces 
(2-6 kN) to obtain an average crushing strength of 80 N to 
240 N and evaluated for physical and release characteristics 
as depicted. Increasing the compression force increased 
hardness and extended disintegration time but led to lower 
friability as depicted in Table IV. This phenomenon might 
be attributed to the formation of more condensed compact 
with increased compression force. However, hardness 
showed no impact on the drug release pattern as the tablets 
were disintegrating into individual pellets in the dissolution 
vessels. As the overall composition contained a large frac-
tion of microcrystalline cellulose, the effect of crospovidone 
and polyethylene glycol level was found to have minimal 
impact on the disintegration time of the tablets hence the 
dissolution profile.
FIGURE 3 - A. Scanning electron micrographs of pellets prepared using sodium alginate as polymer. B. Calcium chloride-treated 
pellets.
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TABLE IV - Physical characterization data of compressed tablets using optimized composition










TAB #2 2-3 80-120 6.4 ± 0.1 0.86 45
3-5 120-180 6.6 ± 0.1 0.32 75
5-6 180-240 6.8 ± 0.1 0.11 150
Comparison of release from uncompressed 
pellets and MUPS tablets
Sodium alginate pellets (Figure 3) treated with cal-
cium chloride solution were compressed into disintegrat-
ing tablets using the compositions listed in Table II, at an 
optimum crushing strength of 160 N, and were evaluated 
by in vitro drug release studies. A dissolution study of six 
tablets was conducted as per the specified method and 
the release profile compared with uncompressed pellets 
(Figure 4).
The release profile of the MUPS tablets was identical 
to the release from the uncompressed pellets. The similar-
ity in the release profiles could be attributed to the absence 
of a thin film of rate-controlling polymer as in the case of 
reservoir type pellets which are prone to damage during 
applied compression forces. In the present study, each 
pellet was presumed to behave like a monolithic matrix 
mini tablet distributed within the cushioning diluent blend 
where the drug release was not dependent on the status and 
nature of the extended release film. The pellets positioned 
on the surface of the tablet were visually inspected using a 
magnifying glass for any physical deformities on the pellet 
surface. Individual pellets subjected to compression force 
FIGURE 4 - In vitro dissolution profiles of sertraline from pellets 
containing (-♦-) 20%w/w plain sodium alginate, (-■-) Calcium 
chloride-treated pellets and (-▲-) compressed tablets.
FIGURE 5 - Scanning electron micrograph of segregated 
individual pellet from the tablet surface directly exposed to the 
tooling surface during compression.
through direct contact with the tooling surface were slowly 
segregated manually and observed under scanning electron 
microscope. From the scanning electron micrographs, 
segregated pellets were found to be physically modified 
with loss of spherical shape due to flattening of the part 
of the surface being pressed in the direction of the applied 
force (Figure 5).
However, minor physical deformities or changes in 
shape are not expected to have significant impact on the 
release profile of the matrix pellets. This can be attributed 
to the presence polymer uniformly distributed within 
each pellet and whenever pellets encounter minor damage 
during compression, polymer within the pellet would still 
control drug release. Hence, only negligible alterations in 
drug release from both uncompressed pellets and the tab-
lets were observed. Scanning electron micrographs (Figure 
6) of the tablets showed well-distributed pellets in the dilu-
ent blend where pellets remained separate from each other 
preventing fusion and formation of non-disintegrating 
matrix mass. Pellets were intact and no pellets were found 
to be fragmented by the applied compression force within 
the diluent blend. This was possible by keeping the pellet 
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percent at 30%w/w where individual pellets remained well 
separated and protected from the compression deformities.
Content uniformity and Acceptance Value (AV)
In the present study, content uniformity of the ten 
compressed tablet was evaluated by measuring the sertra-
line content in individual tablets. The acceptance value of 
the compressed tablet was found to be 18.7 for TAB #1 
composition containing Avicel PH 102 only as the filler. 
The higher AV indicates the poor ability of Avicel PH102 
in preventing segregating tendency as previously reported 
(Beckert, Lehmann, Schmidt, 1998). The variation in the 
content can be due to the differences between density and 
size of the pellets compared to the diluent blend (0.4g/cc) 
which may cause segregation of the pellets. Moreover, 
when compressing the tablets using a single punch on a 
12-station compression machine, the residence time of 
the blend in the feed frame is longer hence the possibility 
of preferential movement of the pellets into the die cavity 
increases, leading to variation in pellet uniformity within 
the tablets.
Influence of Filler on AV
To evaluate the effect of filler, three different com-
positions (TAB # 1-3) were tried as shown in Table 2. 
In the composition TAB #2, around 30 % w/w of Avicel 
PH 102 was replaced with Avicel PH 101 and the blend 
compressed into tablets reducing the AV value to 12.2. 
In another approach, 30 % of Avicel PH 102 was milled 
(18R, Quadro comill, at high speed) and Avicel PH 101 
was replaced with the milled microcrystalline cellulose 
wherein the AV value was 14. This phenomenon of ob-
taining lower acceptance values could be attributed to the 
combination of free flowing (PH 102) and poorly flowing 
(PH 101 or milled) excipient in the diluent blend which 
might restrict the preferential movement of the pellets 
from the blend into the die cavities. Generally, obtain-
ing content uniformity is difficult during compression of 
pellets into tablets due to various factors other than blend 
characteristics such as, blend residence time, operational 
equipment vibrations, number of toolings installed during 
compression etc. However, we predict a better uniformity 
with the TAB #2 compositions by running the compression 
machine with a complete set of tooling.
Influence of extrusion screen aperture size
To evaluate the influence of screen aperture size, 
wet mass of the composition #F11was extruded using 
1.0 mm, 1.2 mm and 1.5 mm screens. These pellets were 
dried and mixed with extra-granular excipients (TAB #2) 
and compressed into MUPS tablets. The tablets showed 
satisfactory physical characteristics. No significant differ-
ence in the dissolution profile of these tablets was observed 
(Figure 7).
However, as the pellet size increased, the AV value 
was found to rise due to increased segregation tendency 
of the pellets (Figure 8). Based on this study, a screen 
aperture size of 0.8 mm was considered most suitable for 
extrusion of pellets to be compressed into tablets.
Influence of Pellet Percentage (%w/w) in the 
composition
Pellet proportion in the composition was increased 
from 30 % to 40 % and 60 % w/w by replacing the filler 
FIGURE 6 - Scanning electron micrograph of compressed tablet 
indicating distribution of matrix pellets within the diluent blend.
FIGURE 7 - Effect of extruder screen aperture size, (-♦-) 
0.8mm, (-■-) 1.0 mm, (-▲-) 1.2mm and (-■-) 1.5mm, on in 
vitro sertraline release.
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composition. Accordingly, tablet weight was reduced 
(Table II) and compressed using suitable tooling. Tablets 
showed satisfactory physical characteristics. However, 
there was significant impact on the in vitro dissolution 
profile in the tablets (Figure 9).
There was no significant difference in the drug re-
lease profile of the tablets containing 30 – 40%w/w pellets. 
At these levels, the tablets showed comparable physical 
characteristics and disintegration times. However, the tab-
lets containing 60%w/w pellet failed to behave like rapidly 
disintegrating tablets in the dissolution vessels. As the 
percentage of pellets was increased, pellets were distrib-
uted closer in the diluent blend and underwent deforma-
tion leading to fusion of pellets into a non-disintegrating 
pellet mass consequently reducing drug release. This is in 
accordance with previous studies, confirming that tablets 
containing pellets below 60% w/w showed satisfactory 
results (Debunne et al., 2004).
FIGURE 8 - Effect of extrusion screen aperture size (0.8 mm, 
1.0 mm, 1.2 mm & 1.5 mm) on Acceptance Value of tablets.
FIGURE 9 – Effect of pellet percentage (-♦-) 30% w/w, 
(-■-) 40% w/w and (-▲-) 60% w/w in tablet composition on in 
vitro sertraline release.
Stability study evaluation of compressed tablets
MUPS tablets prepared using sodium alginate (cal-
cium chloride treated) pellets were subjected to stability 
study and evaluated for drug content and in vitro release 
profile. No significant change in the drug content was ob-
served (99.2% w/w) compared to its initial assay content 
(98.9% w/w), respectively for the tablets prepared using 
sodium alginate-containing pellets. In vitro release profile 
of the tablets after completing the 3M accelerated stability 
study was studied and results are given in Figure 10.
CONCLUSION
Using various polymers, matrix pellets were suc-
cessfully prepared. The desired drug release was achieved 
from the alginate-containing pellets treated with saturated 
solution of calcium chloride. The drug release from matrix 
pellets and compressed tablets using these pellet was found 
to be similar. Acceptance value was easily achieved using a 
combination of Avicel PH 102 and Avicel PH 101 as fillers 
in the diluent blend. Further, the extrusion/spheronization 
technique can be explored to prepare extended release ma-
trix type pellets which can substitute reservoir-type pellets 
in preparing the MUPS tablets. Future research could be 
dedicated to exploring other techniques to obtain greater 
uniformity of drug content in MUPS tablets.
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